Journal
NEURODEGENERATIVE DISEASES
Volume 7, Issue 1-3, Pages 139-142Publisher
KARGER
DOI: 10.1159/000289224
Keywords
Alzheimer's disease biomarkers; Isoprostane; Mild cognitive impairment; Oxidative stress
Categories
Funding
- [PO1AG14449]
- [PO1AG09466]
- [P50AG10161]
- NATIONAL INSTITUTE ON AGING [R01AG043375, P30AG010161, P01AG014449, P01AG009466] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD). The pathobiological changes related to AD occur long before the overt clinical symptoms. The plasma lipid peroxidation enzyme F2-isoprostane has been suggested as a biomarker to detect the progression from mild cognitive impairment (MCI) to AD. Objective: To test whether plasma and urine F2-isoprostane was diagnostic for dementia in living people. Methods: Plasma and urine were collected from 222 Religious Orders Study participants with a clinical diagnosis of no cognitive impairment, MCI or AD at time of fluid collection. Isoprostane levels were determined using gas chromatography/mass spectroscopy. Results: Plasma and urine F2-isoprostane levels did not differ between the three clinical groups. Postmortem neuropathologic diagnosis of subjects who died during the course of the study was not associated with baseline blood or plasma F2-isoprostane levels. Conclusions: In living people, plasma or urine isoprostane levels were not sensitive enough to discriminate between individuals with a clinical diagnosis of no cognitive impairment, MCI or AD. Copyright (C) 2010 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available